US EditionPublished • loading... • Updated
Beat Childhood Cancer Research Consortium at Penn State College of Medicine and Aminex Therapeutics Announce National Clinical Trial for Pediatric Patients with High-Risk Cancers
Summary by Newswise
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Beat Childhood Cancer Research Consortium at Penn State College of Medicine and Aminex Therapeutics Announce National Clinical Trial for Pediatric Patients with High-Risk Cancers
Researchers at Penn State College of Medicine, in collaboration with Aminex Therapeutics, Inc., today announced the start of a national pediatric clinical trial to evaluate an investigational treatment for children and young adults with neuroblastoma, central nervous system tumors and sarcomas.
·Charlottesville, United States
Read Full Article
Beat Childhood Cancer Research Consortium at Penn State College of Medicine and Aminex Therapeutics announce national clinical trial for pediatric patients with high-risk cancers
Researchers at Penn State College of Medicine, in collaboration with Aminex Therapeutics, Inc., today announced the start of a national pediatric clinical trial to evaluate an investigational treatment for children and young adults with neuroblastoma, central nervous system (CNS) tumors and sarcomas. “We are excited to build on the potential of diflouromethyleflornithine (DFMO) treatment in… Source
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
